Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine for MDD with Imminent Suicide Risk
NCT02133001Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Esketamine with Placebo (2 arms). Primary endpoint: Montgomery Asberg Depression Rating Scale at 4 hours. Started May 2014; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02133001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02133001.